{"organizations": [], "uuid": "3cb2f4be6300268130dd0043e16d92d02d702d98", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180226.html", "section_title": "Archive News &amp; Video for Monday, 26 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-dechra-pharmaceuticals-says-hy-rev/brief-dechra-pharmaceuticals-says-hy-revenue-up-11-pct-idUSFWN1QG02N", "country": "US", "domain_rank": 408, "title": "BRIEF-Dechra Pharmaceuticals Says HY Revenue Up 11 Pct", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.932, "site_type": "news", "published": "2018-02-26T15:32:00.000+02:00", "replies_count": 0, "uuid": "3cb2f4be6300268130dd0043e16d92d02d702d98"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-dechra-pharmaceuticals-says-hy-rev/brief-dechra-pharmaceuticals-says-hy-revenue-up-11-pct-idUSFWN1QG02N", "ord_in_thread": 0, "title": "BRIEF-Dechra Pharmaceuticals Says HY Revenue Up 11 Pct", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-dechra pharmaceuticals says hy", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "dechra pharmaceuticals plc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 26 (Reuters) - Dechra Pharmaceuticals Plc:\n* SAYS REPORTED GROUP REVENUE FOR SIX MONTHS ENDED 31 DECEMBER 2017 INCREASED BY 11.2% AT CONSTANT EXCHANGE RATE\n* SAYS EUROPEAN PHARMACEUTICALS REVENUE GROWTH WAS 5.8% AT CONSTANT EXCHANGE RATE FOR SIX MONTHS ENDED 31 DECEMBER 2017\n* DECHRA PHARMACEUTICALS - NORTH AMERICAN PHARMACEUTICALS REVENUE GROWTH WAS 20.7% AT CONSTANT EXCHANGE RATE FOR SIX MONTHS ENDED 31 DECEMBER 2017\n* DECHRA PHARMACEUTICALS - ‍HY UNDERLYING OPERATING PROFIT GROWTH OF 22.3% AT CER (22.6% AT AER) WITH OPERATING MARGIN EXPANSION OF 220 BPS TO 24.6%​\n* ‍HY UNDERLYING DILUTED EPS GROWTH OF 19.8% TO 37.58 PENCE​\n* HY ‍UNDERLYING PROFIT BEFORE TAXATION INCREASED BY 17.6% AT CER TO £44.3 MILLION​\n* ‍DECLARE AN INTERIM DIVIDEND OF 7.33 PENCE PER SHARE​ * ‍CURRENT TRADING CONTINUES IN LINE WITH MANAGEMENT EXPECTATIONS​ Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-26T15:32:00.000+02:00", "crawled": "2018-02-27T15:09:16.020+02:00", "highlightTitle": ""}